In vivo CRISPR therapy successfully reduces hereditary angioedema attacks in first Phase III trial
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 patients ...
15 Jun 17:20 · Medical Xpress
Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.
14 Jun 02:52 · News-Medical
last updated on 15 Jun 21:39